<DOC>
	<DOCNO>NCT00486434</DOCNO>
	<brief_summary>The purpose Phase III study evaluate efficacy safety oral salmon calcitonin treatment patient osteoarthritis knee .</brief_summary>
	<brief_title>Efficacy Safety Oral Salmon Calcitonin Patients With Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Medical history symptom knee osteoarthritis Any disease medication affect bone cartilage . Any clinical sign laboratory evidence disease , Investigator 's opinion would preclude participant adhere Protocol complete trial . Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Osteoarthritis , oral salmon calcitonin , treatment , efficacy , tolerability</keyword>
</DOC>